Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study - Concepedia

Concepedia

Publication | Closed Access

Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

18

Citations

17

References

2022

Year

Tiago Torres, Maria João Paiva Lopes, Margarida Gonçalo, Cristina Claro, Maria Júlia Ribeiro de Oliveira, Joana Gomes, Ana Paula Vieira, Patrícia Amoedo, Miguel Alpalhão, Miguel Nogueira,

Journal of Dermatological Treatment

Abstract

Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.

References

	Year	Citations
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, New England Journal of Medicine	2016	2K
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, The Lancet AllergyAtopic DermatitisAllergy MedicineModerate-to-severe Atopic DermatitisSkin Allergy	2017	1.2K
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t Marjolein de Bruin‐Weller, Diamant Thaçi, Catherine Smith, British Journal of Dermatology	2017	468
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Journal of the American Academy of Dermatology AllergyAtopic DermatitisAllergy MedicineClinical EpidemiologySkin Allergy	2019	205
IL-4 abrogates T <sub>H</sub> 17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells Emmanuella Guenova, Yuliya Skabytska, Wolfram Hoetzenecker, Proceedings of the National Academy of Sciences	2015	175
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases Jennifer D. Hamilton, Sivan Harel, Brian N. Swanson, Clinical & Experimental Allergy	2021	174
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker, Allergy	2019	146
Quality of life and disease severity in patients with atopic dermatitis Jesper Grønlund Holm, Tove Agner, Maja‐Lisa Clausen, Journal of the European Academy of Dermatology and Venereology	2016	116
Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series Linde E. M. de Wijs, Nga Nguyen, A.C.M. Kunkeler, British Journal of Dermatology	2019	115
Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre Caroline Meyer Olesen, Jesper Grønlund Holm, Line Brok Nørreslet, Journal of the European Academy of Dermatology and Venereology	2019	98

Page 1